Sangamo chief executive Sandy Macrae has said the company is "surprised and extremely disappointed" by Pfizer's decision to hand back rights to its experimental gene therapy for haemophilia A ...

(Reuters) -Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development agreement, sending its shares down nearly 64% in extended trade.

Shares of Sangamo Therapeutics have plummeted more than 56% over the past few days after Pfizer announced it had terminated its partnership to develop an investigational gene therapy product to treat ...

Shares of Sangamo Therapeutics slumped after the company filed to terminate its deal with pharmaceutical company Pfizer. The company's stock fell 55% to $1.02 in after-hours trading Monday.